Compare · CMPS vs CMPX
CMPS vs CMPX
Side-by-side comparison of COMPASS Pathways Plc (CMPS) and Compass Therapeutics Inc. (CMPX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. CMPS focuses on Biotechnology: Pharmaceutical Preparations, while CMPX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- CMPS is the larger of the two at $1.63B, about 4.4x CMPX ($367.4M).
- Over the past year, CMPS is up 152.2% and CMPX is down 21.0% - CMPS leads by 173.3 points.
- CMPS has been more active in the news (14 items in the past 4 weeks vs 2 for CMPX).
- CMPX has more recent analyst coverage (23 ratings vs 15 for CMPS).
- Company
- COMPASS Pathways Plc
- Compass Therapeutics Inc.
- Price
- $11.77-2.77%
- $2.03+0.00%
- Market cap
- $1.63B
- $367.4M
- 1M return
- +25.39%
- +11.85%
- 1Y return
- +152.25%
- -21.01%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 14
- 2
- Recent ratings
- 15
- 23
COMPASS Pathways Plc
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics to treat solid tumors and hematologic malignancies. The company is leveraging its proprietary StitchMabs and common light-chain enabled multi specific platforms to identify multi specifics and combinations of antibody therapeutics that could be advanced to the clinic. Its lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. The company is also developing CTX-8371, a bispecific antibody that targets PD-1 and PD-L1. In addition, it is developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Latest CMPS
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Director Karydas Daphne
- SEC Form 4 filed by Director Santini Gino
- SEC Form 4 filed by Director Gover Justin D.
- SEC Form 4 filed by Director Jonas Jeffrey M
- SEC Form 4 filed by Director Riley Wayne Joseph
- SEC Form 4 filed by Director Mcquade Robert
- SEC Form 4 filed by Director Norton David Y
- SEC Form 4 filed by Director Tregoning Kathleen
- SEC Form 3 filed by new insider Tregoning Kathleen
Latest CMPX
- Compass Therapeutics to Participate in Upcoming June Investor Events
- Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
- Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.
- Compass Therapeutics to Participate in Upcoming May Investor Events
- SEC Form 10-Q filed by Compass Therapeutics Inc.
- Compass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
- Amendment: Chief Accounting Officer Lerner Neil bought $28,350 worth of shares (15,000 units at $1.89), increasing direct ownership by 4% to 397,500 units (SEC Form 4)
- Amendment: General Counsel Anderman Jonathan bought $47,250 worth of shares (25,000 units at $1.89), increasing direct ownership by 15% to 196,000 units (SEC Form 4)
- General Counsel Anderman Jonathan was granted 25,000 shares, increasing direct ownership by 15% to 196,000 units (SEC Form 4)